Dr Anthony Fok Neurologist and Neuro-ophthalmologist MS Trials Dr Anthony Fok Neurologist and Neuro-ophthalmologist
Research and Development
IL-37 Study Studying the role of a Interleukin-37 in inflammatory diseases Thought: IL-37 is an inhibitor of inflammation Check IL-37 levels in patients with inflammatory diseases and compare to patients without diseases Need: Consent and blood taken. Future: this may lead to drug development
Vitamin D is thought to play a role in MS PrevANZ Patients with a first clinical attack – Clinically isolated Syndrome Test different doses of Vitamin D3 See whether it can delay or prevent a second episode that would lead to diagnosis of MS Double blind Placebo controlled Treatment for 12 months Collect blood and urine Vitamin D – thought o play a role in MS. Since geographical areas with lower levels of UV radiation – ie have lower vit D synthesis in the skin have higher incidences of MS. Vitamin D3 (cholecalciferol) is produced by the human body in response to sunlight and is also available through dietary sources, such as fish. Safety Efficacy/safety Efficacy/safety and compare to other drug
Phase IV trial for Tecfidera (dimethyl Fumarate) ESTEEM trial Phase IV trial for Tecfidera (dimethyl Fumarate) Include: all patients starting Tecfidera Followup every 6 months Monitor adverse effects You need to complete questionnaires at each clinic visit – can be done online Phase IV study – done after intervention has been marketed – monitor the effectiveness of the approved intervention and collect info on adverse effects
Multicentre, randomised, double blinded placebo controlled study AFFINITY STUDY Multicentre, randomised, double blinded placebo controlled study Relapsing Remitting MS Add on therapy to other therapies - Interferon (beta1a, beta 1b, beta1a) Dimethyl fumerate Nataluzimab Dx: RRMS EDSS 2-6 MS disease duration <20 years Relapse within 24 months and new lesions on MRI Beta 1a avonex, betaferon – beta 1 b
Ask your friendly neurologist or MS nurse